Cytokinetics stock heads into four HFSA presentations

Published on 10/08/2026 at 04:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cytokinetics stock posted USD 28.62 million in Q2 revenue and a USD 1.50 GAAP loss per share. Four aficamten presentations run from October 10 to October 12, 2026.

CYTK, US23282W6057, Illustration mit AI erstellt.

Cytokinetics (ISIN US23282W6057) stock was last at USD 61.12 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, with a daily change of -0.37 percent. The company is heading into four aficamten presentations at the Heart Failure Society of America meeting, giving investors a near-term clinical checkpoint.

Four aficamten presentations ahead

Cytokinetics announced on October 2, 2026, that two late-breaking presentations on October 12 will cover global efficacy and exercise performance results from the ACACIA-HCM trial of aficamten in nonobstructive hypertrophic cardiomyopathy.

The same release schedules an October 10 presentation on right ventricular function and pulmonary coupling from SEQUOIA-HCM, plus an October 11 session on aficamten dosing and safety in ACACIA-HCM. The company also plans to submit a supplemental new drug application for aficamten in nonobstructive HCM in the fourth quarter of 2026.

Revenue beats the Q2 consensus

MarketBeat reported that second-quarter 2026 revenue reached USD 28.62 million, above the USD 17.59 million consensus, while revenue fell 57.1 percent from the year-earlier quarter. GAAP earnings per share came to negative USD 1.50, beating the negative USD 1.63 consensus.

The comparison reflects a business still moving from development toward commercialization. Markets Insider reported a second-quarter GAAP net loss of USD 198.76 million, compared with USD 134.37 million in the year-earlier period.

Analyst targets stay above the quote

MarketBeat said on October 4, 2026, that 18 analysts rated the stock Buy, one rated it Hold and one rated it Sell. The resulting Moderate Buy consensus carried an average price target of USD 106.00, which lies 73.5 percent above the USD 61.12 Nasdaq quote.

Markets Insider reported on October 5, 2026, that H.C. Wainwright reiterated a Buy rating and set a USD 140.00 price target, while Needham maintained Buy with a USD 112.00 target.

Stock remains below its yearly high

Cytokinetics had a market capitalization of USD 7.6 billion on October 7, 2026, with 2,395,556 shares traded. Its 52-week range was USD 54.30 to USD 88.31, placing the latest quote USD 27.19 below the yearly high.